Biokine targets the CXCR4/CXCL12 axis which is critically involved in regulating stem cell mobilization and in the development and progression of cancer.
+ More
BKT140 - A potent CXCR4 antagonist with a unique stem cell mobilization activity and anti-cancer properties. Completed Phase I/IIa study in multiple myeloma patients in 2010.
Biokine is developing a series of anti inflammatory and anti-cancer agents that are in clinical ,pre-clinical and discovery phase.
June 9-12 2011 Biokine to present the anti lymphoma and anti myeloma effect of BKT140 at the 16th Congress of the European Hematology Association in London.
